Suppr超能文献

循环血浆 microRNA-101a 在冠心病严重程度中的诊断效用。

Diagnostic utility of circulating plasma microRNA-101a in severity of coronary heart disease.

机构信息

Department of Cardiology, The 2nd Hospital of Harbin Medical University, 246 Xuefu Road, Nangang District, Harbin, 150086, China.

出版信息

Ir J Med Sci. 2021 Nov;190(4):1391-1396. doi: 10.1007/s11845-021-02512-7. Epub 2021 Jan 21.

Abstract

BACKGROUND

For evaluating the severity of coronary heart disease (CHD), coronary arteriography may not be available everywhere due to technical limitations. MicroRNA-101a (miR-101a) associated with inflammation and cholesterol homeostasis. However, whether it related to presence and stratification of CHD is still unknown.

AIM

We aim to evaluate the value of miR-101a in stratifying CHD patients.

METHODS

We enrolled 200 CHD patients and 100 controls, and 200 CHD patients were divided into two groups of low and high SYNTAX score (SYNTAX score ≤ 22 versus SYNTAX score ≥ 33). Intergroup comparisons of miR-101a level were compared among the controls and two groups of low and high SYNTAX score. Correlation between miR-101a and blood lipid profiles was analyzed. The logistic regression analysis were conducted to evaluate the risk factors of CHD.

RESULTS

Relative level of miR-101a in the controls, SYNTAX score ≤ 22 and SYNTAX score ≥ 33 group were 4.61 (1.24-8.91), 3.28 (0.58-6.75) and 2.29 (1.04-3.62), respectively (p < 0.001). All lipid profiles significantly associated with miR-101a expression (all p < 0.001). The odds ratio (OR) of miR-101a in univariate analysis was 0.41 (95% CI, 0.33-0.52). After adjusting for the traditional risk factors, such as blood profiles and history of smoking, the odds ratio of miR-101a was 0.63 (95% CI, 0.47-0.43), which closely associated with CHD (p = 0.002).

CONCLUSIONS

Circulating miR-101a may be considered as a novel biomarker for evaluating the presence and severity of CHD.

摘要

背景

由于技术限制,并非所有地方都能进行冠状动脉造影术来评估冠心病(CHD)的严重程度。微小 RNA-101a(miR-101a)与炎症和胆固醇稳态有关。然而,它是否与 CHD 的存在和分层有关尚不清楚。

目的

我们旨在评估 miR-101a 在 CHD 患者分层中的价值。

方法

我们纳入了 200 例 CHD 患者和 100 例对照者,并将 200 例 CHD 患者分为低和高 SYNTAX 评分(SYNTAX 评分≤22 与 SYNTAX 评分≥33)两组。比较对照组和低、高 SYNTAX 评分两组之间 miR-101a 水平的组间差异。分析 miR-101a 与血脂谱之间的相关性。采用 logistic 回归分析评估 CHD 的危险因素。

结果

对照组、SYNTAX 评分≤22 组和 SYNTAX 评分≥33 组 miR-101a 的相对水平分别为 4.61(1.24-8.91)、3.28(0.58-6.75)和 2.29(1.04-3.62)(p<0.001)。所有血脂谱均与 miR-101a 表达显著相关(均 p<0.001)。单因素分析中 miR-101a 的比值比(OR)为 0.41(95%CI,0.33-0.52)。在调整了包括血脂和吸烟史在内的传统危险因素后,miR-101a 的 OR 为 0.63(95%CI,0.47-0.43),与 CHD 密切相关(p=0.002)。

结论

循环 miR-101a 可作为评估 CHD 存在和严重程度的新型生物标志物。

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验